{"filing":{"accession_number":"0001193125-26-339292","cik":"0001488039","ticker":"ATOS","company_name":"ATOSSA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"atos-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526339292/atos-20260807.htm"},"events":[{"id":26130,"run_id":23732,"accession_number":"0001193125-26-339292","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses second quarter 2026 financial results for Atossa Therapeutics through a press release dated August 7, 2026, attached as Exhibit 99.1. The disclosure includes operating expenses ($8.7M for Q2 2026), R\u0026D expenses ($4.9M), G\u0026A expenses ($3.8M), and interest income ($0.2M), along with comparisons to prior-year periods and detailed breakdowns of expense categories. This is a standard quarterly earnings release for a clinical-stage biopharmaceutical company, material to investors assessing the company's financial position and cash burn rate.","company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27155,"accession_number":"0001193125-26-339292","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses second quarter 2026 financial results for Atossa Therapeutics through a press release dated August 7, 2026, attached as Exhibit 99.1. The disclosure includes operating expenses ($8.7M for Q2 2026), R\u0026D expenses ($4.9M), G\u0026A expenses ($3.8M), and interest income ($0.2M), along with comparisons to prior-year periods and detailed breakdowns of expense categories. This is a standard quarterly earnings release for a clinical-stage biopharmaceutical company, material to investors assessing the company's financial position and cash burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:08:42.651654+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27155,"accession_number":"0001193125-26-339292","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses second quarter 2026 financial results for Atossa Therapeutics through a press release dated August 7, 2026, attached as Exhibit 99.1. The disclosure includes operating expenses ($8.7M for Q2 2026), R\u0026D expenses ($4.9M), G\u0026A expenses ($3.8M), and interest income ($0.2M), along with comparisons to prior-year periods and detailed breakdowns of expense categories. This is a standard quarterly earnings release for a clinical-stage biopharmaceutical company, material to investors assessing the company's financial position and cash burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:08:42.651654+00:00","company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","filing_date":"2026-08-07"}]}